EP2813215A4 - 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method therefor - Google Patents
2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method thereforInfo
- Publication number
- EP2813215A4 EP2813215A4 EP12868324.0A EP12868324A EP2813215A4 EP 2813215 A4 EP2813215 A4 EP 2813215A4 EP 12868324 A EP12868324 A EP 12868324A EP 2813215 A4 EP2813215 A4 EP 2813215A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation
- tetraisopropyl
- method therefor
- lipid microsphere
- biphenol lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title 2
- 150000002632 lipids Chemical class 0.000 title 1
- 239000004005 microsphere Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5015—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5089—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2012100256112A CN102525921B (en) | 2012-02-06 | 2012-02-06 | 2,2',6,6'-tetraisopropyl-4,4'-bigeminy phenol lipid microsphere preparation and preparation method thereof |
PCT/CN2012/072031 WO2013117022A1 (en) | 2012-02-06 | 2012-03-07 | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method therefor |
Publications (3)
Publication Number | Publication Date |
---|---|
EP2813215A1 EP2813215A1 (en) | 2014-12-17 |
EP2813215A4 true EP2813215A4 (en) | 2015-07-08 |
EP2813215B1 EP2813215B1 (en) | 2016-07-13 |
Family
ID=46334755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP12868324.0A Active EP2813215B1 (en) | 2012-02-06 | 2012-03-07 | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method therefor |
Country Status (6)
Country | Link |
---|---|
US (2) | US20140370101A1 (en) |
EP (1) | EP2813215B1 (en) |
JP (1) | JP5748926B2 (en) |
CN (1) | CN102525921B (en) |
CA (1) | CA2865777C (en) |
WO (1) | WO2013117022A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525921B (en) | 2012-02-06 | 2013-08-07 | 西安力邦制药有限公司 | 2,2',6,6'-tetraisopropyl-4,4'-bigeminy phenol lipid microsphere preparation and preparation method thereof |
CN104557532B (en) * | 2015-01-13 | 2017-03-01 | 西安力邦制药有限公司 | Bigeminy benzene derivative and its application |
CN104546809B (en) * | 2015-01-13 | 2018-08-24 | 西安力邦制药有限公司 | Application of 3,3 ', 5,5 '-tetra isopropyls-the 4,4 '-bigeminy phenol in preventing and treating cerebral arterial thrombosis |
CN112336868A (en) * | 2020-10-28 | 2021-02-09 | 西安力邦医美科技有限公司 | Polyethylenimine matrine lipid microsphere antifungal preparation and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
WO2007052288A2 (en) * | 2005-08-05 | 2007-05-10 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405593D0 (en) * | 1994-03-22 | 1994-05-11 | Zeneca Ltd | Pharmaceutical compositions |
GB9514878D0 (en) * | 1995-07-20 | 1995-09-20 | Danbiosyst Uk | Vitamin E as a solubilizer for drugs contained in lipid vehicles |
IN186588B (en) * | 1999-07-28 | 2001-10-06 | Vinod Daftary Gautam Dr | |
SE0001865D0 (en) * | 2000-05-19 | 2000-05-19 | Astrazeneca Ab | Management of septic shock |
IN188924B (en) * | 2001-03-01 | 2002-11-23 | Bharat Serums & Vaccines Ltd | |
US20060148776A1 (en) * | 2003-03-13 | 2006-07-06 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
CN1478465A (en) * | 2003-07-14 | 2004-03-03 | 丽 佟 | Biphenyl diester liquid medicinal composition containing fat |
US20050255154A1 (en) * | 2004-05-11 | 2005-11-17 | Lena Pereswetoff-Morath | Method and composition for treating rhinitis |
WO2008023384A1 (en) * | 2006-08-24 | 2008-02-28 | Bharat Serums & Vaccines Ltd. | Propofol emulsion compositions for intravenous administration |
CN101804043B (en) * | 2010-04-30 | 2012-04-11 | 西安力邦制药有限公司 | Application of 2-phenylphenol and derivatives thereof to medicine for treating epilepsia |
CN101940549B (en) * | 2010-08-27 | 2012-04-25 | 北京中海康医药科技发展有限公司 | Flurbiprofen axetil medium-chain and long-chain fat emulsion and preparation method thereof |
CN102525921B (en) | 2012-02-06 | 2013-08-07 | 西安力邦制药有限公司 | 2,2',6,6'-tetraisopropyl-4,4'-bigeminy phenol lipid microsphere preparation and preparation method thereof |
-
2012
- 2012-02-06 CN CN2012100256112A patent/CN102525921B/en active Active
- 2012-03-07 JP JP2014555918A patent/JP5748926B2/en active Active
- 2012-03-07 CA CA2865777A patent/CA2865777C/en active Active
- 2012-03-07 US US14/374,220 patent/US20140370101A1/en not_active Abandoned
- 2012-03-07 EP EP12868324.0A patent/EP2813215B1/en active Active
- 2012-03-07 WO PCT/CN2012/072031 patent/WO2013117022A1/en active Application Filing
-
2016
- 2016-04-28 US US15/141,517 patent/US10154967B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040225022A1 (en) * | 2003-05-09 | 2004-11-11 | Desai Neil P. | Propofol formulation containing reduced oil and surfactants |
WO2007052288A2 (en) * | 2005-08-05 | 2007-05-10 | Bharat Serums & Vaccines Ltd. | Intravenous propofol emulsion compositions having preservative efficacy |
Non-Patent Citations (2)
Title |
---|
OGATA M. ET AL.: "Solubilization of dipropofol, an antibacterial agent, using saccharide and ascorbic acid", BIOL. PHARM. BULL., vol. 30, no. 8, August 2007 (2007-08-01), pages 1565 - 1568, XP002739972 * |
See also references of WO2013117022A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP2813215A1 (en) | 2014-12-17 |
US10154967B2 (en) | 2018-12-18 |
EP2813215B1 (en) | 2016-07-13 |
CN102525921A (en) | 2012-07-04 |
JP5748926B2 (en) | 2015-07-15 |
JP2015506378A (en) | 2015-03-02 |
WO2013117022A1 (en) | 2013-08-15 |
CN102525921B (en) | 2013-08-07 |
US20160235684A1 (en) | 2016-08-18 |
CA2865777C (en) | 2015-09-22 |
US20140370101A1 (en) | 2014-12-18 |
CA2865777A1 (en) | 2013-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1209599A1 (en) | Products including capsules, uses and preparation thereof | |
EP2881395A4 (en) | Piperazinotrizole compound, preparation method therefor, and use thereof in drug preparation | |
IL238064B (en) | Poxvirus-containing formulation, method for the preparation of a freeze-dried formulation and uses thereof | |
EP2693336A4 (en) | Virtual machine administration system, and virtual machine administration method | |
EP2884394A4 (en) | Administration system and administration method | |
ZA201404625B (en) | Polycyclic derivatives, preparation method and medical uses thereof | |
IL238223B (en) | An antigen mhc nanoparticle complex, method of preparation and composition comprising the same | |
EP2594281A4 (en) | Insulin-lipid complex, preparation method therefor, and preparation thereof | |
ZA201400188B (en) | Substituted cinnamamide derivative, preparation method and use thereof | |
EP2813495A4 (en) | 2-arylbenzofuran-7-formamide compounds, preparation method and use thereof | |
EP2924042A4 (en) | Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof | |
HK1202857A1 (en) | Benzodioxole derivative and preparation method and use thereof | |
HK1199458A1 (en) | Sterol derivative, preparation method therefor and use thereof | |
EP2868317A4 (en) | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol soft capsule and method for preparing same | |
HK1175159A1 (en) | Graphite block and the preparation method thereof | |
EP2813215A4 (en) | 2,2',6,6'-tetraisopropyl-4,4'-2-biphenol lipid microsphere preparation and preparation method therefor | |
EP2805956A4 (en) | Gambogenic acid derivatives, preparation method and application thereof | |
EP2752419A4 (en) | Spirobenzylamine-phosphine, preparation method therefor and use thereof | |
EP2895168A4 (en) | Tetrandrine pharmaceutical formulations and method | |
EP2837624A4 (en) | 4-substituent-2-hydroxylmorpholine-3-one and preparation method thereof | |
HK1212968A1 (en) | Aminocyclobutane derivatives, method for preparing same and the use thereof as drugs | |
EP2634184A4 (en) | C-arylglucoside derivative, preparation method therefor, and use thereof | |
EP2786989A4 (en) | 2-alkyl-or-aryl-substituted tanshinone derivatives, and preparation method and application thereof | |
EP2789657A4 (en) | Fuchsin dye, preparation method and use thereof | |
EP2889292A4 (en) | 2-substituted-2h-1, 2, 3-triazole derivative and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20140811 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/05 20060101ALI20150528BHEP Ipc: A61K 9/107 20060101AFI20150528BHEP Ipc: A61K 47/12 20060101ALI20150528BHEP Ipc: A61K 47/24 20060101ALI20150528BHEP Ipc: A61P 25/08 20060101ALI20150528BHEP |
|
RA4 | Supplementary search report drawn up and despatched (corrected) |
Effective date: 20150608 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
INTG | Intention to grant announced |
Effective date: 20160429 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: REF Ref document number: 811705 Country of ref document: AT Kind code of ref document: T Effective date: 20160715 Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602012020569 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: LERMERRAIBLE PATENT- UND RECHTSANWALTS PARTGMB, CH |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MG4D |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MP Effective date: 20160713 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 811705 Country of ref document: AT Kind code of ref document: T Effective date: 20160713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: IT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161113 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161013 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161114 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: ES Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161014 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602012020569 Country of ref document: DE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20161013 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
26N | No opposition filed |
Effective date: 20170418 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: C/O MAIL BOXES ETC. FELDBERGSTRASSE 67, 4057 BASEL (CH) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170307 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20170307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20120307 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PCAR Free format text: NEW ADDRESS: HERISAUERSTRASSE 81, 9200 GOSSAU SG (CH) |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20160713 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20220502 Year of fee payment: 11 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 602012020569 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R073 Ref document number: 602012020569 Country of ref document: DE |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20230307 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: S28 Free format text: APPLICATION FILED |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230307 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230307 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231003 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: S28 Free format text: RESTORATION ALLOWED Effective date: 20240219 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R074 Ref document number: 602012020569 Country of ref document: DE |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20240129 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20230331 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20240320 Year of fee payment: 13 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: FR Effective date: 20240119 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20240501 Year of fee payment: 13 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20231003 |
|
PGRI | Patent reinstated in contracting state [announced from national office to epo] |
Ref country code: DE Effective date: 20240408 |